-
Mashup Score: 6FDA Accepts NDA for Ensartinib in Metastatic ALK-Positive NSCLC - 2 month(s) ago
The regulatory agency set an action date of December 28, 2024 for ensartinib as a treatment for those with ALK-positive non–small cell lung cancer.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2
A cohort study for patients with non–small cell lung cancer found an overall survival benefit when targeted therapies were utilized.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Case 4: 71-Year-Old Diagnosed with Stage IIIA NSCLC Experiencing Pneumonitis After Chemo-IO Treatment - 2 month(s) ago
Dr. Gregory Gan presents Case 4, featuring a 71-year-old diagnosed with Stage IIIA NSCLC experiencing pneumonitis following Chemo-IO treatment, prompting a discussion with expert insight on the monitoring and management of this condition.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 7Newer TKIs Show Better Intracranial Responses in ROS1+ NSCLC - 2 month(s) ago
In the first article of a 2-part series, Christine Bestvina, MD, discussed the role of the newer tyrosine kinase inhibitor repotrectinib for patients with non–small cell lung cancer that is positive for a ROS1 mutation.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0FDA Approval Marks Amivantamab's Milestone in EGFR+ NSCLC - 2 month(s) ago
In this episode, Joshua K. Sabari, MD, discusses the FDA approval of amivantamab plus chemotherapy as a first-line treatment for patients with EGFR exon 20 insertion mutation-positive non-small cell lung cancer.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Genomic discordances and heterogeneous mutational burden, PD-L1 expression and immune infiltrates of non-small cell lung cancer metastasis - 2 month(s) ago
Aims To investigate the genomic discordances and heterogeneous mutational burden, PD-L1 expression and immune cell (IC) infiltrates of non-small cell lung cancer (NSCLC) metastasis. Methods Surgical samples from 41 cases of NSCLC with metastatic tumours (MTs) and paired primary tumours (PTs) were collected. PD-L1 expression and ICs were quantified using image-based immunohistochemistry profiling. Whole exome sequencing was employed to explore discrepancies in genomic characteristics, tumour mutational burden (TMB) and tumour neoantigen burden (TNB) in 28 cases. Results Non-synonymous mutations in MTs were slightly more than in PTs, with only 42.34% of mutations shared between paired PTs and MTs. The heterogeneity of TMB showed no significant difference (p=0.785) between MTs and PTs, while TNB significantly increased in MTs (p=0.013). MTs generally exhibited a higher density of PD-L1+ cells and a higher tumour proportion score with a lower density of IC infiltrates. Subgroup analysis co
Source: jcp.bmj.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 1The Surgeon’s Role in Managing Patients with Resectable NSCLC | STS - 2 month(s) ago
In this video, Dr. Leah Backhus, thoracic surgeon and professor of cardiothoracic surgery at Stanford Medicine, discusses the surgeon’s role in managing patients with resectable non-small cell lung cancer.
Source: www.sts.orgCategories: General Medicine News, Cardiac SurgeryTweet
-
Mashup Score: 1THIO/Cemiplimab Elicits Responses in Advanced NSCLC Cohort - 2 month(s) ago
Developers also announced that they completed enrollment of patients with non–small cell lung cancer in the phase 2 THIO-101 trial.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4
This study analyzed all metastatic categories of the current tumor, node, and metastasis (TNM) classification of non-small cell lung cancer to propose modifications of the M component in the next edition (9th) of the classification.
Source: www.jto.orgCategories: General Medicine News, Onc News and JournalsTweet-
This study analyzed all metastatic categories of the TNM classification of #NSCLC to propose modifications of the M component in the 9th edition, the data validates the 8th edition M1a & M1b categories. Read more including a proposal re: the M1c category: https://t.co/YyN6PyDF4z https://t.co/4ch3qq5ks3
-
-
Mashup Score: 5
The next-generation SRI was previously granted an Orphan Drug Designation in November 2023 and its safety and efficacy are currently being evaluated in clinical trials.
Source: www.pharmacytimes.comCategories: General Medicine News, PayerTweet
The FDA has accepted a new drug application for ensartinib as a treatment for adult patients with metastatic ALK-positive non–small cell lung cancer. #NSCLC | @US_FDA @FDAOncology https://t.co/Qex92zO4Hx